Navigation Links
Cholesterol-lowering Drugs Reduce Risk of Stroke, Heart Attack

People whose cholesterol improved after one month on cholesterol-lowering drugs called statins reduced their risk of stroke and heart attack, according to research that will be presented at the American Academy of Neurologys 59th Annual Meeting in Boston, April 28 May 5, 2007.

The study enrolled 4,731 people within one to six months of having a stroke or transient ischemic attack, or mini-stroke, and with no history of heart disease. Half of the participants received the cholesterol-lowering drug atorvastatin and half received a placebo. The participants were then followed for an average of four and a half years.

For each 10-percent decrease in LDL, or low-density lipoprotein bad cholesterol, the risk of stroke was reduced by four percent and the risk of heart attack was reduced by seven percent. The average decrease in LDL cholesterol after one month on atorvastatin was 53 percent.

These findings reinforce the importance of controlling cholesterol, said study author Pierre Amarenco, MD, of Denis Diderot University in Paris, France, and Fellow member of the American Academy of Neurology. Its encouraging to see that reducing cholesterol so quickly can have positive long-term effects.

People with higher levels of HDL, or high-density lipoprotein good cholesterol, at the beginning of the study and after one month had a lower risk of stroke.


'"/>




Page: 1

Related medicine news :

1. Cholesterol-lowering therapy benefits older people also
2. Cholesterol-lowering drug Found To greatly Reduce the risk of stroke and heart attack
3. Growing Popularity of Cholesterol-lowering Drugs Raises Concern
4. Cholesterol-lowering Drug Effective at Halting Early Atherosclerosis
5. Lean Protein Could Be Key to Obesity Drugs
6. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
7. Nasal Spray Could Take Drugs Direct to Brain.
8. Emphasis to ban Drugs ads by Doctors
9. Osteoporosis Drugs: right time to take-off
10. Drugs disrupt formation of blood vessels
11. Drugs to stop burgeon of HIV
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: